0A8E Xeris Biopharma Inc

TIDM0A8E

RNS Number : 1122O

J.P. Morgan Securities LLC

05 October 2021

Ap19

AMENDMENT

   FORM   8.3 
   IRISH  TAKEOVER   PANEL 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH  TAKEOVER   PANEL ACT,  1997,  TAKEOVER  RULES, 2013 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY   INFORMATION 
 
Name of person dealing      J.P. Morgan Securities 
 (Note 1)                    LLC 
Company dealt in            Xeris Pharmaceuticals, 
                             Inc. 
                            ====================== 
Class of relevant security  $0.001 common stock 
 to which the dealings 
 being disclosed relate 
 (Note 2) 
                            ====================== 
Date of dealing             04 October 2021 
                            ====================== 
 
   2.         INTERESTS AND SHORT POSITIONS 

(a) Interests and short positions (following dealing) in the class of relevant

security   dealt   in   (Note   3) 
 
                                         Long               Short 
                             Number      (%)     Number       (%) 
                             =========  ======  ===========  ====== 
(1) Relevant securities       2,093,525 3.15        15,295 0.02 
                             -----------------  ------------------- 
(2) Derivatives (other 
 than options) 
                             -----------------  ------------------- 
(3) Options and agreements 
 to purchase/sell 
                             -----------------  ------------------- 
Total                         2,093,525 3.15        15,295 0.02 
                             -----------------  ------------------- 
 
 
   1.       DEALINGS  (Note   4) 
   (a)      Purchases and sales 
 
 
    Purchase/sale             Number of relevant securities        Price per unit 
                                                                       (USD) 
 
                                                                      (Note 5) 
Sale(Borrow Return)                  78,200                          N/A 
 
   Purchase(Loan                     21,181                           N/A 
      return) 
                                       15                         2.3900 USD 
        Sale 
                     ======================================  ==================== 
 
   (b)      Derivatives transactions (other than options transactions) 
 
Product name,  Nature of transaction  Number of relevant   Price per 
 e.g. CFD       (Note 6)               securities           unit 
                                       (Note 7)             (USD) (Note 
                                                            5) 
 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing,  selling, purchasing or varying 
 
Product     Writing,      Number of       Exercise  Type,            Expiry  Option 
 name,       selling,      securities      price     e.g. American,   date    money paid/received 
 e.g. call   purchasing,   to which                  European                 per unit 
 option      varying       the option                etc.                     (Note 5) 
             etc.          relates (Note 
                           7) 
 
 
   (ii)      Exercising 
 
Product name,             Number of securities      Exercise price 
 e.g. call option                                    per unit (Note 
                                                     5) 
 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
Nature of transaction         Details      Price per unit 
 (Note 8)                                   (if applicable) 
                                            (Note 5) 
 
 

Ap21

   2.       OTHER  INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the

voting rights of any relevant securities under any option referred to on this form or relating to

  the   voting   rights   or   future   acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If

 none, this should   be   stated. 

None

   Is a Supplemental Form 8 attached?  (Note   9)                                              NO 
 
Date of disclosure             05 October 2021 
Contact name                  Alwyn Basch 
                              ================ 
Telephone number              0207 742 7407 
                              ================ 
If a connected EFM, name      N/A 
 of offeree/offeror with 
 which connected 
                              ================ 
If a connected EFM, state     N/A 
 nature of connection (Note 
 10) 
                              ================ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEFSSFMIEFSESS

(END) Dow Jones Newswires

October 05, 2021 12:06 ET (16:06 GMT)

Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024